4//SEC Filing
Orexigen Therapeutics, Inc. 4
Accession 0001181431-15-002033
CIK 0001382911operating
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 5:33 PM ET
Size
7.1 KB
Accession
0001181431-15-002033
Insider Transaction Report
Form 4
Booth Mark D
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2015-02-03+88,925→ 88,925 totalExercise: $5.34Exp: 2025-02-02→ Common Stock (88,925 underlying) - Award
Common Stock
2014-05-30$5.25/sh+4,218$22,145→ 8,028 total
Footnotes (3)
- [F1]Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.
- [F2]1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/3/2015, so that all of the shares of the stock subject to the option shall be vested on 2/3/2019, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date.
- [F3]Not applicable.
Documents
Issuer
Orexigen Therapeutics, Inc.
CIK 0001382911
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001382911
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 5:33 PM ET
- Size
- 7.1 KB